{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:14:30Z","timestamp":1762272870692,"version":"build-2065373602"},"reference-count":34,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Association between calcium channel blockers (CCBs) or functional inhibitors of acid sphingomyelinase (FIASMAs) use and decreased mortality in people with COVID-19 has been reported in recent studies. Since amlodipine is both a CCB and a FIASMA, the aim of this study was to investigate the association between chronic amlodipine use and the survival of people with hypertension infected with COVID-19. This retrospective cohort study used data extracted from the medical records of adult inpatients with hypertension and laboratory-confirmed COVID-19 between 1 March 2020 and 31 August 2020 with definite outcomes (discharged from hospital or deceased) from Erasme Hospital (Brussels, Belgium). We re-analyzed the data of the retrospective cohort study using only the 184 patients (103 males, 81 females) with a mean age of 69.54 years (SD = 14.6) with hypertension. The fifty-five participants (29.9%) receiving a chronic prescription of amlodipine were compared with the 129 patients who did not receive a chronic prescription of amlodipine. Univariate and multivariate logistic regressions were used to explore the relationships between mortality and sex, age, comorbidities, smoking, and amlodipine status. Out of the 184 participants, 132 (71.7%) survived and 52 (28.3%) died. The mortality rates were, respectively, 12.73% (n = 7) and 34.88% (n = 45) for the amlodipine and non-amlodipine groups. Multivariate logistic regression was significant (Chi square (5) = 29.11; p &lt; 0.0001). Chronic kidney disease and malignant neoplasm were significant predictors as well as amlodipine status. For chronic kidney disease and malignant neoplasm, the odds ratio with 95% confidence interval (95% CI) were, respectively, 2.16 (95% CI: 1.04\u20134.5; p = 0.039) and 2.46 (95% CI: 1.01\u20136.01; p = 0.047). For amlodipine status the odds ratio was 0.29 (95% CI: 0.11\u20130.74; p = 0.009). The result of the present study suggests that amlodipine may be associated with reduced mortality in people with hypertension infected with COVID-19. Further research and randomized clinical trials are needed to confirm the potential protective effect of amlodipine in people with hypertension infected with COVID-19.<\/jats:p>","DOI":"10.3390\/ph15030380","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T21:48:42Z","timestamp":1647899322000},"page":"380","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Association of Amlodipine with the Risk of In-Hospital Death in Patients with COVID-19 and Hypertension: A Reanalysis on 184 COVID-19 Patients with Hypertension"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1719-916X","authenticated-orcid":false,"given":"Gwenol\u00e9","family":"Loas","sequence":"first","affiliation":[{"name":"Department of Psychiatry, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (ULB), 1070 Brussels, Belgium"},{"name":"Research Unit (ULB 266), H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (ULB), 1070 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Van de Borne","sequence":"additional","affiliation":[{"name":"Department of Cardiology, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (ULB), 1070 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Darquennes","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (ULB), 1070 Brussels, Belgium"},{"name":"Research Unit (ULB 266), H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles (ULB), 1070 Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-0957","authenticated-orcid":false,"given":"Pascal","family":"Le Corre","sequence":"additional","affiliation":[{"name":"P\u00f4le Pharmacie, Service Hospitalo-Universitaire de Pharmacie, CHU de Rennes, 35033 Rennes, France"},{"name":"Irset (Institut de Recherche en Sant\u00e9, Environnement et Travail)-UMR_S 1085, CHU Rennes, INSERM, EHESP, University of Rennes, 35000 Rennes, France"},{"name":"Laboratoire de Biopharmacie et Pharmacie Clinique, Facult\u00e9 de Pharmacie, Universit\u00e9 de Rennes 1, 35043 Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/emph\/eoaa046","article-title":"Conflicts over calcium and the treatment of COVID-19","volume":"9","author":"Crespi","year":"2021","journal-title":"Evol. Med. Public Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1515\/jbcpp-2021-0334","article-title":"Using of calcium channel blockers in patients with COVID-19: A magic bullet or a double-edged sword?","volume":"33","author":"Sadeghpopur","year":"2021","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"ref_4","first-page":"e20746","article-title":"Why Pulmonary Vasodilation May Be Part of a Key Strategy to Improve Survival in COVID-19","volume":"13","author":"Solaimanzadeh","year":"2021","journal-title":"Cureus"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Berlansky, S., Sallinger, M., Grabmayr, H., Humer, C., Bernhard, A., Fahrner, M., and Frischauf, I. (2022). Calcium Signals during SARS-CoV-2 Infection: Assessing the Potential of Emerging Therapies. Cells, 11.","DOI":"10.3390\/cells11020253"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41421-020-00235-0","article-title":"Calcium channel blocker amlodipine besylate is associated with reduced case fatality rate of COVID-19 patients with hypertension","volume":"6","author":"Zhang","year":"2020","journal-title":"Cell Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1021\/acsmedchemlett.0c00521","article-title":"Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2","volume":"11","author":"Ghahremanpour","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"586572","DOI":"10.3389\/fimmu.2020.586572","article-title":"Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2","volume":"11","author":"Xiao","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pickard, A., Calverley, B.C., Chang, J., Garva, R., Gago, S., Lu, Y., and Kadler, K.E. (2021). Discovery of re-purposed drugs that slow SARS-CoV-2 replication in human cells. PLoS Pathog., 17.","DOI":"10.1101\/2021.01.31.428851"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1021\/acsinfecdis.1c00023","article-title":"Inhibitors of L-Type Calcium Channels Show Therapeutic Potential for Treating SARS-CoV-2 Infections by Preventing Virus Entry and Spread","volume":"7","author":"Straus","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hoagland, D.A., Clarke, D.J.B., M\u00f8ller, R., Han, Y., Yang, L., Wojciechowicz, M.L., Lachmann, A., Oguntuyo, K.Y., Stevens, C., and Lee, B. (2020). Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds. Biorxiv.","DOI":"10.1101\/2020.07.12.199687"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102210","DOI":"10.1016\/j.dsx.2021.102210","article-title":"Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis","volume":"15","author":"Alsagaff","year":"2021","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41440-021-00786-z","article-title":"Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: A systematic review and meta-analysis","volume":"45","author":"Kow","year":"2021","journal-title":"Hypertens. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000315101","article-title":"Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical Applications","volume":"26","author":"Kornhuber","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Loas, G., and Le Corre, P. (2021). Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070691"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1080\/22221751.2020.1829082","article-title":"Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine","volume":"9","author":"Schloer","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Dechaumes, A., Nekoua, M.P., Belouzard, S., Sane, F., Engelmann, I., Dubuisson, J., Alidjinou, E.K., and Hober, D. (2021). Fluoxetine Can Inhibit SARS-CoV-2 In Vitro. Microorganisms, 9.","DOI":"10.3390\/microorganisms9020339"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Brunotte, L., Zheng, S., Mecate-Zambrano, A., Tang, J., Ludwig, S., Rescher, U., and Schloer, S. (2021). Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro. Pharmaceuticals, 13.","DOI":"10.3390\/pharmaceutics13091400"},{"key":"ref_19","first-page":"2339","article-title":"Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro","volume":"178","author":"Schloer","year":"2021","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"849095","DOI":"10.3389\/fphar.2022.849095","article-title":"Difficulty in repurposing SSRIs and other antidepressants with functional inhibition of acid sphingo-myelinase in COVID-19 infection","volume":"13","author":"Loas","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_21","first-page":"e8069","article-title":"Nifedipine and Amlodipine Are Associated with Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19","volume":"12","author":"Solaimanzadeh","year":"2020","journal-title":"Cureus"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Darquennes, G., Le Corre, P., Le Moine, O., and Loas, G. (2021). Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030226"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/cpt.2317","article-title":"Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study","volume":"110","author":"Hoertel","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e14124","DOI":"10.1111\/ijcp.14124","article-title":"Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial","volume":"75","author":"Kalami","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_25","first-page":"e14957","article-title":"Comment on \u2018Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial\u2019","volume":"75","author":"Loas","year":"2021","journal-title":"Int. J. Clin. Pr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/22221751.2021.2020598","article-title":"Pharmacologically induced endolysosomal cho-lesterol imbalance through clinically licensed drugs itraconazole and fluoxetine impairs Ebola virus infection in vitro","volume":"11","author":"Kummer","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1126\/science.1258758","article-title":"Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment","volume":"347","author":"Sakurai","year":"2015","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.clpt.2005.04.005","article-title":"Adult AIDS Clinical Trials Group A5159 Protocol Team. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers","volume":"78","author":"Glesby","year":"2005","journal-title":"Clin. Pharm. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-2125.2000.00283.x","article-title":"Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine","volume":"50","author":"Vincent","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/emph\/eoaa036","article-title":"Evolutionary medical insights into the SARS-CoV-2 pandemic","volume":"2020","author":"Crespi","year":"2020","journal-title":"Evol. Med. Public Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10928-018-9574-0","article-title":"Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic\/pharmacodynamic model","volume":"45","author":"Mukherjee","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00228-020-03060-2","article-title":"Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs","volume":"77","author":"Courlet","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_33","unstructured":"(Statistica Software, 2005). Statistica Software, Version 7.1."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"100059","DOI":"10.1016\/j.xcrm.2020.100059","article-title":"Charac-terization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia","volume":"1","author":"Pizzorno","year":"2020","journal-title":"Cell Rep. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/3\/380\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:40:07Z","timestamp":1760136007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/3\/380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ph15030380"],"URL":"https:\/\/doi.org\/10.3390\/ph15030380","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2022,3,21]]}}}